Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriatic arthritis.

D D Gladman1, J Brockbank

  • 1University of Toronto Psoriatic Arthritis Clinic and Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada. dafna.gladman@utoronto.ca

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?

The British journal of dermatology·2020
Same author

Disease course patterns in systemic lupus erythematosus.

Lupus·2018
Same author

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis research & therapy·2018
Same author

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Lupus·2018
Same author

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Lupus·2018
Same author

Antimalarial-induced cardiomyopathy: a systematic review of the literature.

Lupus·2017

Psoriatic arthritis (PsA) affects psoriasis patients, presenting unique inflammatory joint patterns. Current treatments offer limited benefit, necessitating research into novel therapies targeting PsA

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Psoriatic arthritis (PsA) affects 5-42% of psoriasis patients, characterized by distinct inflammatory joint patterns.
  • Unlike rheumatoid arthritis, PsA is typically seronegative, asymmetrical, and affects spinal, sacroiliac, and distal joints.
  • PsA exhibits variable severity, ranging from mild non-destructive disease to severe erosive arthropathy with bone lysis and ankylosis.

Purpose of the Study:

  • To review the distinct characteristics of psoriatic arthritis compared to rheumatoid arthritis.
  • To evaluate the efficacy of current and emerging therapies for psoriatic arthritis.
  • To highlight the need for greater understanding of PsA pathogenesis and natural history for effective treatment.

Main Methods:

  • Literature review and synthesis of existing research on psoriatic arthritis.

Related Experiment Videos

  • Comparison of psoriatic arthritis pathogenesis and cytokine profiles with rheumatoid arthritis.
  • Analysis of current and investigational treatment strategies for psoriatic arthritis.

    • Main Results:

    • Psoriatic arthritis has a unique immunopathogenesis and cytokine profile distinct from rheumatoid arthritis.
    • Conventional therapies like methotrexate and sulphasalazine show limited efficacy in delaying PsA damage.
    • Emerging biological agents, extrapolated from rheumatoid arthritis, require further study for PsA-specific manifestations like osteolysis and new bone formation.

    Conclusions:

    • Greater understanding of psoriatic arthritis pathogenesis and natural history is crucial.
    • Novel therapies must address PsA-specific features, including skin involvement, osteolysis, and fibrosis.
    • Targeted and effective treatment strategies for psoriatic arthritis are needed.